Cambridge Investment Research Advisors
ITCI

Cambridge Investment Research Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,701
Closed -$349K – 3236
2022
Q1 		$349K Buy
+5,701
New +$296K ﹤0.01% 2420

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cambridge Investment Research Advisors's ITCI Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2022, closing a stake of 5,701 shares — an estimated $349K sold.

Cambridge Investment Research Advisors first reported a position in ITCI in Q1 2022 and held it in 1 quarter. The position peaked at $349K in Q1 2022. 266 funds tracked by Wall St. Rank hold ITCI as of Q2 2022.

  • Cambridge Investment Research Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 5,701 Intra-Cellular Therapies Inc. shares in Q2 2022, an estimated $349K.
  • Cambridge Investment Research Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Intra-Cellular Therapies Inc. position peaked at $349K in Q1 2022.
  • 266 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.